Combination of Pancreatic Cancer Drugs from Tango and Revolution Shows High Response Rate in Early Trial
Tango Therapeutics and Revolution Medicines announced early-stage clinical trial results showing their combination drug therapy produced durable responses in a large majority of pancreatic cancer patients. Revolution's daraxonrasib has recently generated significant attention in oncology for unprecedented outcomes in pancreatic cancer treatment. The results suggest potential for improved therapeutic options in a disease with historically poor prognosis.
Tango Therapeutics reported positive early-stage clinical trial data for a combination treatment pairing its drug vopimetostat with Revolution Medicines' daraxonrasib in pancreatic cancer patients. The combination demonstrated durable responses in the majority of trial participants, according to data revealed Monday. Revolution's daraxonrasib has recently become a focal point in the oncology field following earlier announcements of unprecedented outcomes. The trial represents an important next step in evaluating whether combining these two experimental medicines could offer improved therapeutic benefit compared to single-agent approaches. The results come as pancreatic cancer remains one of the most challenging malignancies to treat.
What's missing
The specific response rate percentage, number of trial participants, trial phase details beyond 'early-stage,' patient population characteristics, mechanism of action for both drugs, timeline for further development, and any adverse event data are not provided in the available excerpt.
What different sources said
- STAT NewsCenter
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
Related
Person dies from rare Murray Valley Encephalitis virus in Western Australia
A person has died after contracting Murray Valley Encephalitis, a rare mosquito-borne virus, while travelling in Western Australia's north, marking the first reported death from the virus in WA this year. The individual was likely exposed in early May in the West Kimberley region, about 2,000 kilometres north of Perth, before being transferred to a Perth hospital where they died. Health authorities are urging residents and tourists to protect themselves from mosquito bites as the region enters its peak tourism season, noting the virus can cause serious brain infection though complications remain rare.
Shigellosis outbreak in Wayanad rises to three confirmed cases; health officials launch investigation
A third student tested positive for shigellosis in Wayanad, Kerala, following an outbreak at Mar Baselios AUP School, bringing confirmed cases to three. The bacterial infection has caused symptoms in 473 people total, with 58 currently hospitalized, prompting health officials to investigate the source and implement stricter sanitation measures. The outbreak highlights concerns about water safety and food hygiene in the region, with authorities conducting well chlorination and inspections of food establishments.
Red-Light Therapy for Hair Loss: Clinical Evidence and Consumer Device Reviews
Wired published a 2026 guide reviewing red-light therapy devices for hair restoration, reporting that clinical studies suggest the treatment can increase blood circulation, reduce inflammation, and support hair follicle growth. Red-light therapy has emerged as an at-home alternative to traditional hair-loss treatments like topical remedies or surgical procedures. The guide matters because hair loss affects millions, and if clinically validated, at-home devices could democratize access to a non-invasive treatment option.